Every Form 4 that AbCellera Biologics Inc. (ABCL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ABCL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ABCL filings page.
AbCellera Biologics Inc. director Michael R. Hayden reported an indirect open-market purchase of 53,613 Common Shares of ABCL on 2026-08-24 at a weighted-average price of $10.64 per share, from multiple trades between $10.49 and $10.70. These shares, totaling 1,373,397 after the purchase, are held by Genworks 2 Consulting, Inc., over which his spouse has sole voting and investment power. Hayden disclaims beneficial ownership except for any indirect pecuniary interest. A separate indirect holding of 118,245 Common Shares is reported as held by his spouse.
AbCellera Biologics Inc. (ABCL) director John S. Montalbano reported purchasing 10,000 Common Shares on 2026-08-18 at $11.03 per share in an open-market or private transaction. After this purchase, he directly holds 251,000 Common Shares, and there is an additional 5,000 Common Shares reported as indirectly owned by his spouse. The filing indicates these transactions were not reported under a Rule 10b5-1 trading plan.
AbCellera Biologics Inc. Chief Financial Officer Andrew Booth purchased 37,200 Common Shares on August 14, 2026 at $10.32 per share in an open market or private transaction. Following this trade, he holds 482,800 Common Shares directly and 130,959 Common Shares indirectly, held by his spouse.
AbCellera Biologics Inc. director Michael R. Hayden reported an indirect open-market purchase of 46,387 Common Shares of AbCellera on August 12, 2026 at a weighted-average price of $10.37 per share, with individual trade prices ranging from $10.25 to $10.45.
The acquired shares are held by Genworks 2 Consulting, Inc., over which Hayden’s spouse has sole voting and investment power. Hayden reports 1,319,784 Common Shares held indirectly through Genworks 2 following the transaction and separately 118,245 Common Shares held indirectly by his spouse, and disclaims beneficial ownership of these securities except for any indirect pecuniary interest.
AbCellera Biologics Inc. director Michael R. Hayden reported a bona fide charitable gift of 50,000 Common Shares on August 11, 2026. The donation was made by Genworks 2 Consulting, Inc., which now holds 1,273,397 Common Shares. These shares are held with sole voting and investment power by the reporting person’s spouse, and the reporting person disclaims beneficial ownership except for any indirect pecuniary interest. A separate indirect holding of 118,245 Common Shares is reported as held by the spouse.
AbCellera Biologics Inc. director Lynn Seely received a grant of share options covering 152,207 common shares. The options have an exercise price of $7.85 per share and expire on July 1, 2036. They vest in three equal annual installments beginning July 1, 2027, contingent on continued service.
AbCellera Biologics Inc. director Sandor Victor received a grant of options covering 152,207 common shares on July 1, 2026. These share options have an exercise price of $7.85 per share and expire on July 1, 2036.
The options vest in three substantially equal annual installments, with the first tranche scheduled to vest on July 1, 2027, subject to his continued service with the company. After this grant, he holds options on 152,207 shares directly.
AbCellera Biologics Inc. director Michael R. Hayden received a grant of share options covering 111,701 common shares. The options have an exercise price of $5.27 per share, expire on June 11, 2036, and represent compensation rather than an open-market purchase.
The options vest and become exercisable at the company’s 2027 Annual General Meeting, subject to his continuous service with AbCellera through that date. Following this award, he holds options on a total of 1,011,544 underlying common shares directly.
AbCellera Biologics Inc. director Stephen Quake received a grant of 111,701 share options giving the right to buy an equal number of common shares at an exercise price of $5.27 per share. After this grant, Quake holds share options for a total of 306,633 common shares.
The options vest and become exercisable at the company’s 2027 Annual General Meeting, provided Quake continues to serve the company through that date. This is a compensation-related award rather than an open-market stock trade.
AbCellera Biologics Inc. director John S. Montalbano received a grant of share options giving him the right to buy 111,701 common shares at an exercise price of $5.27 per share. These options vest and become exercisable at the 2027 Annual General Meeting, as long as he continues serving the company. After this grant, he holds 1,141,544 share options in total.
AbCellera Biologics Inc.’s Chief Financial Officer Andrew Booth exercised share options to acquire 250,000 Common Shares at an exercise price of $0.19 per share. Following this transaction, he directly owns 445,600 Common Shares.
The filing also reports 130,959 Common Shares held indirectly through his spouse. The exercised options vested in substantially equal annual installments over six years, with the first tranche vesting on June 15, 2017, subject to his continuous service to the company.
AbCellera Biologics Inc. director John S. Montalbano reported buying additional company stock. On May 14, 2026, he made an open-market purchase of 20,000 Common Shares at $4.77 per share. After this transaction, he holds 241,000 Common Shares directly and 5,000 Common Shares indirectly through his spouse.
Thermopylae Holdings Ltd., a 10% owner of AbCellera Biologics Inc., bought 38,000 common shares in an open-market purchase at a weighted-average price of $3.44 per share, with individual trade prices ranging from $3.42 to $3.45.
After this transaction, Thermopylae Holdings directly owns 56,134,097 AbCellera common shares, reinforcing its already significant stake in the company.
Thermopylae Holdings Ltd., a major shareholder of AbCellera Biologics Inc., reported an open-market purchase of 177,457 common shares at a weighted-average price of $3.27 per share. The filing notes the trades occurred in multiple transactions between $3.19 and $3.40, bringing Thermopylae’s holdings to 56,096,097 common shares.
AbCellera Biologics Inc. Chief Financial Officer Andrew Booth reported an open-market purchase of common shares. He bought 42,600 common shares at a price of $3.42 per share, increasing his direct holdings to 195,600 common shares following the transaction. The filing also reports 130,959 common shares held indirectly through his spouse.
AbCellera Biologics Inc. (ABCL) reported an insider share purchase by a company director. On 11/26/2025, the reporting person bought 50,000 common shares in an open market transaction coded as "P" at a price of $3.5692 per share. After this transaction, the director beneficially owned 221,000 common shares directly.
The filing also notes indirect ownership of an additional 5,000 common shares held by the director’s spouse. The form is filed as a Form 4 for one reporting person and indicates the director relationship to AbCellera Biologics Inc.